Ertugliflozin is an advanced oral treatment for type 2 diabetes mellitus (T2DM). Part of the SGLT2 inhibitor class, it helps lower blood sugar levels by encouraging the body to excrete excess glucose through the urine. This insulin-independent mechanism makes it particularly effective in patients with insulin resistance.
Amber Lifesciences Pvt Ltd, a top pharmaceutical exporter in India to LATAM countries, offers high-quality Ertugliflozin. We serve Latin American nations such as Brazil, Colombia, Mexico, Argentina, and Chile. For reliable sourcing and global B2B support, contact Amber Lifesciences Pvt Ltd today.
What Makes Ertugliflozin Effective?
How It Works
Ertugliflozin blocks sodium-glucose co-transporter 2 (SGLT2) proteins in the kidneys. These proteins normally reabsorb glucose from the urine and return it to the bloodstream. By inhibiting them, the drug:
- Reduces glucose reabsorption
- Promotes urinary glucose excretion (glucosuria)
- Lowers blood glucose levels naturally
Ertugliflozin Clinical Uses & Benefits
- Primary Indication
Type 2 Diabetes Mellitus (T2DM): Helps manage blood sugar levels when paired with healthy lifestyle habits. - Additional Health Benefits
- Mild weight loss from calorie loss through urine
- Reduction in blood pressure due to osmotic diuresis
- Potential cardiorenal benefits (under ongoing study in comparison to other SGLT2 inhibitors)
Ertugliflozin Dosing & Administration
| Dose | Frequency | Notes |
|---|---|---|
| 5 mg or 15 mg | Once daily | Can be consumed on an empty stomach or after food, preferably at the start of the day. |
Dose adjustment is required for patients with reduced kidney function. Use is not advised when eGFR falls below 30 mL/min/1.73 m².
Ertugliflozin Possible Side Effects
Common:
- Increased urination
- Genital yeast infections (especially in women)
- Urinary tract infections (UTIs)
- Thirst
Rare but Serious:
- Diabetic ketoacidosis (DKA) (even with normal blood sugar)
- Fournier’s gangrene (severe genital infection)
- Lower limb amputations (observed with some SGLT2 inhibitors)
- Hypotension or acute kidney injury in at-risk individuals
Who Should Avoid Ertugliflozin?
Avoid use in:
- Individuals with severe kidney impairment (eGFR <30)
- Patients with a history of ketoacidosis
- Those allergic to SGLT2 inhibitors
Ertugliflozin Drug Interactions
| Drug Type | Risk |
|---|---|
| Diuretics | Increased risk of dehydration and low blood pressure |
| Insulin / Sulfonylureas | Higher chance of hypoglycemia |
| Other SGLT2 Inhibitors | Should not be used concurrently |
Comparison: Ertugliflozin vs. Other SGLT2 Inhibitors
Ertugliflozin (marketed as Steglatro) offers a similar mode of action to empagliflozin, canagliflozin, and dapagliflozin, with comparable benefits. It is also available in convenient fixed-dose combinations:
- Segluromet = Ertugliflozin + Metformin
- Steglujan = Ertugliflozin + Sitagliptin
Ertugliflozin Available Brands
- Steglatro (Merck & Pfizer)
- Segluromet
- Steglujan
These formulations facilitate the personalization of treatment based on individual patient needs.
Trusted Supply from Amber Lifesciences Pvt Ltd
Amber Lifesciences Pvt Ltd is a GMP-certified Indian pharmaceutical exporter serving LATAM countries like Brazil, Mexico, Colombia, Chile, Argentina, and Peru. We specialize in producing high-quality SGLT2 inhibitors, including Ertugliflozin, with:
High-quality diabetes medications. We ensure:
- Regulatory Filing & Documentation Services for Worldwide Compliance
- Customized Packaging Solutions for international markets
- Delivering Healthcare Solutions Across 20+ Global Markets
Conclusion
Ertugliflozin is a highly effective option for managing type 2 diabetes, especially when weight and cardiovascular health are also concerns. With its once-daily dosing and insulin-independent mechanism, it simplifies diabetes care while delivering multiple metabolic benefits.
Looking to source Ertugliflozin bulk supply or formulation for your region?
Contact Amber Lifesciences Pvt Ltd—a reliable partner for quality-driven exports across Latin America.
